The Asian Oncology Society 1st Virtual International Conference

 

The Asian Oncology Society 1st Virtual International Conference
E

Residual Disease After Neoadjuvant Therapy - Updates on KATHERINE Trial in HER2+ eBC: Adjuvant T-DM1 vs. Trastuzumab

By The Asian Oncology Society 1st Virtual International Conference FEATURING Edith Perez
By The Asian Oncology Society 1st Virtual International Conference FEATURING Edith Perez
1,358 views
February 18, 2021
Comments 2
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss
Breast
24:13

Efficiency of ICI With Chemo for BC: Cancer Immune Cycle, Tumor Muta…

The Asian Oncology Society 1st Virtual International Conference

S. Glueck

33 views
10:54

Chemo Strategies for mBC: Should We Use Longer 1L Duration to Improv…

The Asian Oncology Society 1st Virtual International Conference

C. Liu

97 views
13:23

Cardiotoxicities and PLD in mBC: Is It More Efficient Than Conventio…

The Asian Oncology Society 1st Virtual International Conference

T. Wei-Wu Chen

84 views
32:25

Residual Disease After Neoadjuvant Therapy - Updates on KATHERINE Tr…

The Asian Oncology Society 1st Virtual International Conference

E. Perez

1.4K views